| Today’s Big NewsApr 15, 2024 |
| By Kevin Dunleavy 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20. |
|
|
|
By Max Bayer Regeneron is joining its pharma peers, launching its own venture capital wing. The New York pharma plans to commit $100 million annually for the first five years. |
By Nick Paul Taylor Eli Lilly and Novo Nordisk faced a third rival for the GLP-1 market last year: counterfeiters. BrandShield helped remove more than 250 websites peddling the blockbuster medicines in 2023, the cybersecurity company told Reuters, as the weight-loss therapies emerged as a major focus of anticounterfeit activity. |
By Conor Hale Though the initial green lights cover spine and orthopedic hardware, Orthobond and Onkos Surgical said their respective disinfectants could shield a wide variety of implants. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
By Fraiser Kansteiner The study paired Columvi, a CD20xCD3 bispecific T-cell engager, with the chemotherapy GemOx (glofitamab-gxbm) in patients who’d tried at least one prior line of therapy and did not qualify for autologous stem cell transplants. |
By James Waldron The FDA has placed a phase 1 trial of Neumora Therapeutics’ schizophrenia drug on hold after preclinical data revealed rabbits dosed with the drug had experienced convulsions. |
By Andrea Park Viatris has spent the last few years shedding various businesses, including its biosimilar and over-the-counter departments, among others—but now, the company is back to making additions. |
By Conor Hale Working with the Clinton Health Access Initiative and the Global Ultrasound Institute, Butterfly aims to provide 500 portable probes to South Africa. |
By Angus Liu After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey. |
By James Waldron A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the microbiome biotech has touted 18-month data as proof it’s on track to launch the drug in acute graft-versus-host disease in two years’ time. |
By Nick Paul Taylor AstraZeneca is sounding the crisis klaxon after spotting an “urgent and growing” global health situation that has “profound economic and environmental implications.” The drugmaker made the comments in response to forecasts of the impact of chronic kidney disease through 2032. |
By Zoey Becker The filling department closure comes as part of a regulatory commitment, a spokesperson said. The site in Kankakee County, Illinois, has been active for 70 years and employs around 1,500 workers. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Monday, April 29, 2024 | 12:30pm ET / 9:30am PTLearn how evolving healthcare delivery impacts product positioning for Integrated Delivery Networks. Discover key messages, stakeholders, and shifts in IDN perceptions post-COVID-19. Claim your spot. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
